PATENT CLAIM ANALYSIS

Application Number: 16113574
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "482000"]

Abstract:
The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

Claim (Index 14):
The pharmaceutical composition of  claim 13 , wherein the hydrophobic film coating polymer comprises ethyl cellulose, the hydrophilic plasticizer comprises polyethylene glycol, the hydrophobic plasticizer comprises dibutyl sebacate, the beta blocker is metoprolol succinate, the binder comprises povidone, and the powder mixture comprises starlac, syloid, crospovidone, and magnesium stearate.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 96.0
- Lexical Diversity: 1.51282
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15554449', '15058533', '15698115', '14379032', '14936963']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7914372445405653
- 35 USC 102 Novelty (BERT): 0.594746117979446
- Combined Prediction Score: 0.7717681318844534
- Mean Citation Score: 411.937388
- Max Citation Score: 595.1677
- Similarity Product: 419.50570233577486

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test